Repressive epigenetic changes at the mglu2 promoter in frontal cortex of 5-HT2A knockout mice

Molecular Pharmacology

Volumn 83, Issue 6, 2013, Pages 1166-1175

  Kurita, Mitsumasa ^a   Moreno, José L ^a   Holloway, Terrell ^a   Kozlenkov, Alexey ^a   Mocci, Giuseppe ^a   García Bea, Aintzane ^a   Hanks, James B ^a   Neve, Rachael ^b   Nestler, Eric J ^a   Russo, Scott J ^a   González Maeso, Javier ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; HISTONE H3; HISTONE H4; METABOTROPIC RECEPTOR 2; SEROTONIN 2A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EPIGENETICS; FRONTAL CORTEX; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ANIMALS; DNA METHYLATION; EARLY GROWTH RESPONSE PROTEIN 1; EPIGENESIS, GENETIC; FRONTAL LOBE; HISTONES; MICE; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84877825156     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.084582     Document Type: Article

References (52)

1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG, and Roth BL (2009) PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29:7124-7136.
2. Agid O, Kapur S, Arenovich T, and Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228-1235. (Pubitemid 37494076)
3. Béïque JC, Imad M, Mladenovic L, Gingrich JA, and Andrade R (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci USA 104:9870-9875. (Pubitemid 47175358)
4. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, and Sanders-Bush E (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72: 477-484. (Pubitemid 47124127)
5. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, McMahon S, Karlsson EK, Kulbokas EJ, 3rd, and Gingeras TR et al. (2005) Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120:169-181. (Pubitemid 40174761)
6. Bhaumik SR, Smith E, and Shilatifard A (2007) Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14:1008-1016. (Pubitemid 350060343)
7. Borrelli E, Nestler EJ, Allis CD, and Sassone-Corsi P (2008) Decoding the epigenetic language of neuronal plasticity. Neuron 60:961-974.
8. Carlsson A, Waters N, and Carlsson ML (1999) Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 46:1388-1395.
9. Celada P, Puig MV, Díaz-Mataix L, and Artigas F (2008) The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: Reversal by antipsychotic drugs. Biol Psychiatry 64:392-400.
10. Davis S, Bozon B, and Laroche S (2003) How necessary is the activation of the immediate early gene zif268 in synaptic plasticity and learning? Behav Brain Res 142:17-30. (Pubitemid 36677587)
11. Dong E, Guidotti A, Grayson DR, and Costa E (2007) Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci USA 104:4676-4681. (Pubitemid 47186284)
12. Dulac C (2010) Brain function and chromatin plasticity. Nature 465:728-735.
13. Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, and Eltit JM et al. (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011-1023.
14. Gewirtz JC and Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23:569-576.
15. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, and Milligan G et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 93-97. (Pubitemid 351355090)
16. González-Maeso J and Sealfon SC (2009a) Agonist-trafficking and hallucinogens. Curr Med Chem 16:1017-1027.
17. González-Maeso J and Sealfon SC (2009b) Psychedelics and schizophrenia. Trends Neurosci 32:225-232.
18. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, and Zhou Q et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439-452. (Pubitemid 46161267)
19. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, and Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836-8843. (Pubitemid 37210895)
20. Gurevich EV and Joyce JN (1997) Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. Biol Psychiatry 42:529-545. (Pubitemid 27425471)
21. Hof PR, Young WG, Bloom FE, Belichenko PV, and Celio MR (2000) Comparative cytoarchitectonic atlas of the C57BL/6 and 129/Sv mouse brains, Elsevier, Amsterdam.
22. Jakovcevski M and Akbarian S (2012) Epigenetic mechanisms in neurological disease. Nat Med 18:1194-1204.
23. Jones MW, Errington ML, French PJ, Fine A, Bliss TV, Garel S, Charnay P, Bozon B, Laroche S, and Davis S (2001) A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci 4: 289-296. (Pubitemid 32194877)
24. Kantrowitz J and Javitt DC (2012) Glutamatergic transmission in schizophrenia: From basic research to clinical practice. Curr Opin Psychiatry 25:96-102.
25. Kouzarides T (2007) Chromatin modifications and their function. Cell 128: 693-705. (Pubitemid 46273577)
26. Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, and Takahashi N et al. (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15:1245-1254.
27. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, and Mahadik SP et al. (2008) Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358-403.
28. Marek GJ, Wright RA, Schoepp DD, Monn JA, and Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292: 76-87. (Pubitemid 30026356)
29. Miyamoto S, Duncan GE, Marx CE, and Lieberman JA (2005) Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104. (Pubitemid 40139590)
30. Moreno JL, Holloway T, Albizu L, Sealfon SC, and González-Maeso J (2011a) Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 493:76-79.
31. Moreno JL, Holloway T, Rayannavar V, Sealfon SC, and González- Maeso J (2013a) Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice. Neurosci Lett 536:69-73.
32. Moreno JL, Holloway T, Umali A, Rayannavar V, Sealfon SC, and González-Maeso J (2013b) Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice. Psychopharmacology (Berl) 225:217-226.
33. Moreno JL, Kurita M, Holloway T, López J, Cadagan R, Martínez-Sobrido L, García-Sastre A, and González-Maeso J (2011b) Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT?A and mGlu? receptors in the adult offspring. J Neurosci 31:1863-1872.
34. Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuellar F, Mocci G, Seto J, Callado LF, and Neve RL et al. (2012) Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem 287:44301-44319.
35. Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, and González-Maeso J (2012) Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol DOI: 10.1016/j.euroneuro.2012.10.006. [Epub ahead of print].
36. Nestler EJ and Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161-1169.
37. Oquendo MA, Russo SA, Underwood MD, Kassir SA, Ellis SP, Mann JJ, and Arango V (2006) Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol Psychiatry 59:235-243. (Pubitemid 43208970)
38. Orkin SH and Hochedlinger K (2011) Chromatin connections to pluripotency and cellular reprogramming. Cell 145:835-850.
39. Peter CJ and Akbarian S (2011) Balancing histone methylation activities in psychiatric disorders. Trends Mol Med 17:372-379.
40. Pin JP, Galvez T, and Prézeau L (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 98:325-354. (Pubitemid 36638547)
41. Ptak C and Petronis A (2008) Epigenetics and complex disease: From etiology to new therapeutics. Annu Rev Pharmacol Toxicol 48:257-276. (Pubitemid 351738154)
42. Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg LH, and Baaré W et al. (2010) Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 67:9-16.
43. Roh TY, Cuddapah S, Cui K, and Zhao K (2006) The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci USA 103:15782-15787. (Pubitemid 44657544)
44. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359. (Pubitemid 38499762)
45. Ruthenburg AJ, Li H, Milne TA, Dewell S, McGinty RK, Yuen M, Ueberheide B, Dou Y, Muir TW, and Patel DJ et al. (2011) Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions. Cell 145: 692-706.
46. Schmid CL, Raehal KM, and Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079-1084. (Pubitemid 351282084)
47. Shelton RC, Sanders-Bush E, Manier DH, and Lewis DA (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158:1406-1415.
48. Sodhi M, Wood KH, and Meador-Woodruff J (2008) Role of glutamate in schizophrenia: Integrating excitatory avenues of research. Expert Rev Neurother 8: 1389-1406.
49. Suganuma T and Workman JL (2008) Crosstalk among Histone Modifications. Cell 135:604-607.
50. Suzuki MM and Bird A (2008) DNA methylation landscapes: Provocative insights from epigenomics. Nat Rev Genet 9:465-476. (Pubitemid 351693975)
51. Tsankova N, Renthal W, Kumar A, and Nestler EJ (2007) Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8:355-367. (Pubitemid 46652469)
52. Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, and Nisenbaum LK (2003) Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28:45-52.